Chemed Aktie - CXM

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

550,00

Gebot

555,00

Fragen

565,00

Volumen

0,00

0,00 Tagesbereich 0,00

480,00 52-Wochen-Bereich 585,00

Handelsende

550,00

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided...

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to launch a new premium advanced skin...

Cardium Reports on Exchange Listing With NYSE AMEX

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the...

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the...

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501...

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue...

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter...

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket...

Cardium Completes $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously...

Cardium Announces $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-5	-0.900900900901	555	555	555	4	555	DE
4	25	4.7619047619	525	585	520	9	542.79411765	DE
12	50	10	500	585	500	9	535.64759036	DE
26	20	3.77358490566	530	585	480	11	525.76054217	DE
52	15	2.80373831776	535	585	480	10	521.65088757	DE
156	15	2.80373831776	535	585	480	10	521.65088757	DE
260	15	2.80373831776	535	585	480	10	521.65088757	DE

CXM - Frequently Asked Questions (FAQ)

What is the current Chemed share price?

The current share price of Chemed is 550,00 €

What is the 1 year trading range for Chemed share price?

Chemed has traded in the range of 480,00 € to 585,00 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMIMedondo Holding AG	0,498 € (91,54%)	270
PA8Paion AG	0,03 € (53,06%)	16,1k
W4VAlphaGen Intelligence Corp	0,0105 € (50,00%)	259,45k
5EPLotus Technology Inc	2,18 € (46,31%)	278
3XS0Gunnison Copper Corp	0,256 € (46,29%)	170,85k
CNWCodon AG	0,013 € (-40,91%)	11,73k
L09Lithium Energi Exploration Inc	0,007 € (-33,33%)	11,2k
9U90Unity Biotechnology Inc	1,172 € (-30,57%)	7,43k
0IU0US Critical Metals Corp	0,035 € (-30,56%)	113,55k
PU11Social Chain AG	0,0102 € (-27,14%)	1,18k
DMLSayona Mining Limited	0,0115 € (4,55%)	6,1M
D7GNel ASA	0,2567 € (-0,66%)	5,41M
3CPXiaomi Corporation	6,439 € (-1,87%)	3,25M
DEZDeutz AG	7,20 € (-1,30%)	2,97M
WIG1Wige Media AG	0,035 € (34,62%)	2,32M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Chemed Corp (CXM)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

CXM Neueste Nachrichten

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

CXM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Chemed Corp (CXM) Börsenkurse

Chemed Corp (CXM)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

CXM Neueste Nachrichten

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

CXM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen